Mechanism underlying long-term regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase during L6 myoblast differentiation

2010 ◽  
pp. n/a-n/a
Author(s):  
Laura Trapani ◽  
Chiara Martini ◽  
Anna Trentalance ◽  
Valentina Pallottini
Keyword(s):  
Coenzyme A ◽  
Myoblast Differentiation ◽  
L6 Myoblast ◽  
Coenzyme A Reductase

Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin

Biochimie ◽  
2011 ◽  
Vol 93 (7) ◽  
pp. 1165-1171 ◽  
Author(s):  
Laura Trapani ◽  
Marco Segatto ◽  
Veronica Simeoni ◽  
Valentina Balducci ◽  
Ashish Dhawan ◽  
...  
Keyword(s):  
Coenzyme A ◽  
Short And Long Term ◽  
Coenzyme A Reductase

scholarly journals P152 The incidence of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies may be higher than we think

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Vikram M K Joseph ◽  
Emily C Rose ◽  
Mark Lloyd ◽  
Christopher J Edwards ◽  
Soha K Amar ◽  
...  
Keyword(s):  
New Zealand ◽  
Coenzyme A ◽  
Average Duration ◽  
Adult Population ◽  
Routine Care ◽  
Proactive Approach ◽  
Routine Assessment ◽  
Testing Criteria ◽  
Coenzyme A Reductase

Abstract Background/Aims  Statins are associated with muscle symptoms, from myalgia with normal CK, to rhabdomyolysis. A sub-group have an autoimmune necrotising myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies. This can present variably, from mild self-limiting illness to severe myopathy unresponsive to statin withdrawal, requiring long-term immunosuppression. A study from New Zealand estimated the incidence of anti-HMGCR-associated myositis to be 1 in 90,000 statin users, and an incidence of 1 in 500,000 has been estimated in a US population. Anti-HMGCR antibodies were first reported in 2010. As they are new, and testing is not widely available, they may be under-recognised in the routine assessment of patients with myopathies. However, detection is important as prompt immunosuppression may be needed. Methods  We compared the 2019 incidence of anti-HMGCR antibodies in Southern England from two different laboratory groups, utilising different testing criteria. The St George’s and Berkshire Surrey Pathology Services (StG/BSPS) laboratories serve a population of 3.25 million and test anti-HMGCR antibodies solely on clinician request. The Southampton laboratory serves a population of 2.33 million and tests anti-HMGCR as part of the immunoblot for all myositis-associated antibodies and where clinical details suggest myositis or ILD. Results  In 2019, 14 tests were performed by StG/BSPS and 662 by Southampton, with anti-HMGCR positives of 5 (36%) and 28 (4.2%) respectively. Adjusted to include only the adult population, the incidence of anti-HMGCR antibodies is 1 in 514,000 in the StG/BSPS area versus 1 in 66,000 in the Southampton area. We estimate statins to be used in 308,000 adults in the StG/BSPS and in 220,000 in the Southampton areas, assuming treatment in 12% of adults and age demographics representative of the national population. This suggests an incidence of anti-HMGCR antibodies of approximately 1 in 62,000 statin users in the StG/BSPS area and 1 in 8,000 statin users in the Southampton area, though statin exposure was not confirmed in all positive cases. Preliminary data from 17 anti-HMGCR positive cases shows that 76% had taken statins, for an average duration of 5.84 years (range 0.75-16 years). Median peak CK was 6489 (range 241-27555). 76% required immunosuppression, of which 70% required two or more different treatments. Conclusion  The 7.7-fold higher incidence from the Southampton laboratory reflects a proactive approach, selecting far more samples for anti-HMGCR assessment than specifically requested by clinicians. This demonstrates under-awareness of this antibody in routine care. We propose adoption of an algorithm to trigger more widespread testing for anti-HMGCR antibodies, to identify cases amongst those with statin-associated myalgia or myositis, and in others without statin exposure. This will lead to better understanding of the spectrum of clinical disease associated with anti-HMGCR antibodies, as well as early detection and treatment of those who develop a necrotising myopathy. Disclosure  V.M.K. Joseph: None. E.C. Rose: None. M. Lloyd: None. C.J. Edwards: None. S.K. Amar: None. T. Forster: None. K.A. Smith: None. R.D. Wheeler: None. P.D.W. Kiely: None.

scholarly journals Effect of Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors on the Long-Term Progression of Rheumatic Mitral Valve Disease

Circulation ◽  
2010 ◽  
Vol 121 (19) ◽  
pp. 2130-2136 ◽  
Author(s):  
Francesco Antonini-Canterin ◽  
Luis M. Moura ◽  
Roxana Enache ◽  
Elisa Leiballi ◽  
Daniela Pavan ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Coenzyme A ◽  
Valve Disease ◽  
Reductase Inhibitors ◽  
Hydroxymethylglutaryl Coenzyme A Reductase ◽  
Coenzyme A Reductase
Sign in / Sign up

Export Citation Format

Share Document